Sign In
Buy PFE
$25.36
-0.200 (-0.783%)
At Close: Jun 03, 2026
Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run
11:10am, Thursday, 13'th Nov 2025
Pfizer (NYSE: PFE) is reportedly offloading its remaining stake in Covid-19 vaccine partner BioNTech SE (NASDAQ: BNTX).
Metsera shareholders vote for $10 billion acquisition by Pfizer
09:18am, Thursday, 13'th Nov 2025
Metsera shareholders on Thursday approved Pfizer's takeover offer worth up to $10 billion, allowing the U.S. pharmaceutical giant re-entry into the lucrative obesity treatment market after a fierce bi
BioNTech says collaboration with Pfizer remains unchanged
08:17am, Thursday, 13'th Nov 2025
BioNTech said on Thursday that its collaboration with Pfizer has not changed, when asked to comment on a report that Pfizer is looking to sell its stake in the German biotech firm.
Should You Forget Pfizer and Buy This Magnificent Drug Stock Instead?
04:55am, Thursday, 13'th Nov 2025
Pfizer and Merck are two of the largest drug companies on the planet. Both companies are dealing with upcoming patent expirations.
3 Healthcare Stocks Topping a 2025 List of Dividend Yields
08:27pm, Wednesday, 12'th Nov 2025
Bristol Myers Squibb has a high dividend yield, is very cheap, and may have better growth prospects than it might seem at first glance. Pfizer now has a 7% yield, and may have found a solution to its
2 Strong Healthcare Stock Picks for Value Investors
10:15am, Wednesday, 12'th Nov 2025
These two tried-and-tested healthcare giants have compelling portfolios and pipelines. Pfizer is moving on from the pandemic era, and a stream of acquisitions has bolstered its pipeline.
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
10:00am, Wednesday, 12'th Nov 2025
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Dave Denton, Chief Financial Officer, Executive Vice Pr
Advyzon Investment Management LLC Buys 4,774 Shares of Pfizer Inc. $PFE
04:38am, Wednesday, 12'th Nov 2025
Advyzon Investment Management LLC grew its holdings in Pfizer Inc. (NYSE: PFE) by 34.2% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Comm
Allworth Financial LP Acquires 66,209 Shares of Pfizer Inc. $PFE
03:41am, Wednesday, 12'th Nov 2025
Allworth Financial LP raised its stake in Pfizer Inc. (NYSE: PFE) by 43.5% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutio
Johnson Fistel Investigates Fairness of Proposed Sale of Metsera
01:57pm, Tuesday, 11'th Nov 2025
SAN DIEGO, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP, has launched an investigation into whether the board members of Metsera, Inc. (NASDAQ: MTSR) breached the
Where Will Pfizer Be in 3 Years?
10:07am, Tuesday, 11'th Nov 2025
Pfizer has a long history of success in the competitive and complex drug sector. The pharmaceutical giant has patent expirations coming in 2027 and 2028.
5 Highest Yielding Dividend Stocks in the S&P 500
09:53am, Tuesday, 11'th Nov 2025
The first thing that comes to mind when we speak about the S&P 500 is the biggest tech companies, high valuations, and fastest-moving giants.
Who's Winning the Intense Battle to Rule the White-Hot GLP-1 Drug Market?
04:25am, Tuesday, 11'th Nov 2025
Eli Lilly's GLP-1 drug is now the world's best-selling drug. Novo Nordisk is struggling with declining market share.
Why a Strong Quarter Wasn't Enough to Send Shares of Pfizer Soaring
04:10am, Tuesday, 11'th Nov 2025
Pfizer's sales and profits came in better than expected for the third quarter. The stock, however, remains down for the year.
Pfizer Inc. (PFE) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology Transcript
03:31am, Tuesday, 11'th Nov 2025
Pfizer Inc. ( PFE ) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology November 10, 2025 8:30 AM EST Company Participants Francesca DeMartino - Chief Investor Relations O
